Form 8-K · Current report
DaVita 8-K, filed Oct 29, 2026
- Filed
- CIK
- 0000927066
- Accession no.
- 0000927066-26-000132
Summary
DaVita Inc. reported third-quarter 2026 consolidated revenues of $3.578 billion, operating income of $499 million, diluted earnings per share of $3.40, and adjusted diluted earnings per share of $3.82. It updated 2026 guidance for adjusted operating income to $2.175–$2.250 billion and adjusted diluted EPS to $14.30–$15.20, and recorded a $62 million non-cash impairment charge related to its China business.
Key points
- DaVita reported Q3 2026 operating cash flow of $519 million and free cash flow of $276 million.
- DaVita repurchased 0.6 million shares at an average price of $186.21 during the quarter and repurchased an additional 0.5 million shares for $87 million through October 27, 2026.
- DaVita updated its 2026 free cash flow guidance to $1.000–$1.250 billion, unchanged from prior guidance.
- As of September 30, 2026, DaVita provided dialysis services to approximately 298,100 patients at 3,269 outpatient dialysis centers.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. On October 29, 2026, DaVita Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The information contained in this Item 2.02 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.